Interdisciplinary approach to the treatment and management of dyslipidemia in Albania
Downloads
The prevalence of dyslipidemia in Albania is approximately 60%. Since the total adult population is 2.173 million, there are about 1.3 million patients with dyslipidemia.
We conducted a descriptive study, through the distribution of questionnaires and interviews of outpatient doctors, laboratory doctors and pharmacists, as some of the most important components of this journey. 100 professionals for each specialty were included in the study.
The medical specialists included in the study during their daily practice are involved in situations of management, treatment and follow-up of patients with dyslipidemia, in a significant percentage; doctors 90-100% and pharmacists with over 70%. Based on the therapeutic alternatives present in our country, it turns out that statins are the most commonly used therapy, and the treatment starts with low doses and in most cases the maximum dosage is not reached, as a result of the side effects that this therapy causes. These professionals are also involved in the long-term follow-up of patients, where in over 80% of cases they suggest returning for consultations every three months, or they do the evaluation of the cardiovascular risk factors for this category of patients, in over 50% of cases.
The role of all medical specialties involved in the management of dyslipidemias consists in strengthening the cooperation and coordination of all components of the healthcare system, and especially of all members of the multidisciplinary team, in the management of dyslipidemias, in order to achieve successful therapeutic results.
Downloads
World Health Organization. Cardiovascular diseases (CVDs). Available from: https://www.who.int/news-room/fact-sheets/detail/cardiovas cular- diseases-(cvds) [Last accessed: September 2020].
Benjamin EJ, Muntner P, Alonso A, et al; American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke sta- tistics-2019 update: a report from the American Heart Association. Circulation. 2019;139(10):e56-e528. doi: 10.1161/CIR.0000000000000659
Thomas A. Gaziano, MD, MSc, Asaf Bitton, MD,* Shuchi Anand, MD,* Shafika Abrahams-Gessel, MS,‡ and Adrianna Murphy, Growing Epidemic of Coronary Heart Disease in Low- and Middle-Income Countries, Curr Probl Cardiol. 2010 Feb; 35(2): 72–115. doi: 10.1016/j.cpcardiol.2009.10.002
McClellan M, Brown N, Califf RM, Warner JJ. Call to Action: Urgent Challenges in Cardiovascular Disease: A Presidential Advisory from theAmerican Heart Association. Circulation. 2019;139(9): E44–E54.
SCORE2 risk prediction algorithms: newmodels to estimate 10-year risk of cardiovascular disease in Europe, European Heart Journal (2021) 00, 1–16
Grundy SM, Stone NJ, Bailey AL, et al. 2018 HA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25): E1082–E1143.
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the Management of Dyslipidaemias: Lipid Modification to Reduce Cardiovascular Risk. Eur Heart J. 2020;1(41):111–188.
Handrean Soran, Ricardo Dent, Paul Durrington, Evidence-based goals in LDL-C reduction. Clin Res Cardiol. 2017 Apr;106(4):237-248. doi: 10.1007/s00392-016-1069-7.
Ross T Tsuyuki, Meagen Rosenthal, Glen J Pearson. A randomized trial of a community-based approach to dyslipidemia management: Pharmacist prescribing to achieve cholesterol targets (RxACT Study). Can Pharm J (Ott). 2016 Sep;149(5):283-292. doi: 10.1177/1715163516662291. Epub 2016 Aug 2.
Toth PP, Granowitz C, Hull M, Anderson A, Philip S. Long-term statin persistence is poor among high-risk patients with dyslipidemia: a real-world administrative claims analysis. Lipids Health Dis. 2019 Sep 16;18(1):175. doi: 10.1186/s12944-019-1099-z.
Su Golder, Davy Weissenbacher, Karen O'Connor, Sean Hennessy, Robert Gross, Graciela Gonzalez Hernandez. Patient-Reported Reasons for Switching or Discontinuing Statin Therapy: A Mixed Methods Study Using Social Media. Drug Saf. 2022 Sep;45(9):971-981. doi: 10.1007/s40264-022-01212-0. Epub 2022 Aug 7.
Alexander Hodkinso, Dialechti Tsimpida, Evangelos Kontopantelis, Martin K Rutter, Mamas A Mamas, Maria Panagioti. Comparative effectiveness of statins on non-high density lipoprotein cholesterol in people with diabetes and at risk of cardiovascular disease: systematic review and network meta-analysis. BMJ. 2022 Mar 24;376:e067731. doi: 10.1136/bmj-2021-067731.
https://fsdksh.gov.al/wp-content/uploads/2021/04/buxheti-ne-vite-2013-2021-5.pdf
Shurdha O, Hasimi E, Petrela E, Goda A. Prevalence of major cardiovascular risk factors among adults in Albania (Prevalenca e faktorëve madhorë të riskut kardiovaskular tek të rriturit në Shqipëri). International Journal of Science and Research (Revista Ndërkombëtare e Shkencës dhe Kërkimit), Vëllimi 4 Botimi 12, 2015.
http://www.instat.gov.al/en/statistical-literacy/gross-domestic-product/
Laney K Jones, et al. Implementation strategies to improve statin utilization in individuals with hypercholesterolemia: a systematic review and meta-analysis. Implement Sci. 2021 Apr 13;16(1):40. doi: 10.1186/s13012-021-01108-0.
Huimin Xu, et al. Impacts of Clinical Pharmacist Intervention on the Secondary Prevention of Coronary Heart Disease: A Randomized Controlled Clinical Study. Front Pharmacol. 2019 Oct 8;10:1112. doi: 10.3389/fphar.2019.01112.
Julie Villeneuve et. al. A cluster randomized controlled Trial to Evaluate an Ambulatory primary care Management program for patients with dyslipidemia: the TEAM study. CMAJ. 2010 Mar 23;182(5):447-55. doi: 10.1503/cmaj.090533.
Copyright (c) 2024 Ina Pasho, Marinela Dibra, Erjona Pasho, Era Goda, Jurgen Burreli, Erjon Troja
This work is licensed under a Creative Commons Attribution 4.0 International License.
